Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 5/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ROS1 | P08922 | 1/20 | 0.41 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16001186 | 0.92 | NTSR1 (0.46) | SUV39H2STAT3PLK1ALKINSR | |
| SCHEMBL23707075 | 0.83 | NTSR1 (0.42) | SUV39H2PLK1ALKINSRIGF1R | |
| SCHEMBL12139624 | 0.83 | DPP4 (0.43) | SUV39H2ALKEGFRALDH1A1 | |
| SCHEMBL23997023 | 0.81 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL310055 | 0.81 | SUV39H2 (0.45) | SUV39H2STAT3PLK1ALKEGFR | |
| SCHEMBL29661369 | 0.81 | SUV39H2 (0.45) | SUV39H2STAT3PLK1ALKEGFR | |
| SCHEMBL23328248 | 0.81 | HSD11B1 (0.42) | PLK1HSD11B1 | |
| SCHEMBL23707018 | 0.80 | L3MBTL3 (0.54) | PLK1ALKEGFRINSRIGF1R | |
| Hydrochloric Acid SCHEMBL29367159 | 0.80 | SUV39H2 (0.44) | SUV39H2STAT3PLK1ALKEGFR | |
| SCHEMBL16001195 | 0.79 | SIRT6 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | SUV39H2 2630/4885STAT3 76/4885PLK1 421/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | SUV39H2 2912/4885STAT3 67/4885PLK1 493/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | SUV39H2 2023/4885STAT3 1098/4885PLK1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.